Humacyte, Inc. — Director's Dealing 2023

Jun 15, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Humacyte, Inc. (HUMA)
CIK: 0001818382
Period of Report: 2023-06-13

Reporting Person: Dougan Brady W (Director, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-06-13	Common Stock	S	4875000	$2.60	Disposed	10490736	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	510161	Direct
Common Stock	1270240	Indirect

Footnotes

F1: The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for the institutional healthcare investor purchasers to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase.